As per the letter attached
LYKALABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.3 pts less than Nifty Microcap 250 and 2.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Lyka Labs reported its Q4 and full year FY2026 results (ended March 31, 2026). The company recorded a net loss of Rs. 14.40 lakhs on standalone basis and Rs. 1,043.56 lakhs on consolidated basis for FY26, compared to profits in FY25. Revenue from operations stood at Rs. 13,470 lakhs (standalone) and Rs. 13,850 lakhs (consolidated). The Board approved an impairment loss of Rs. 2,301.44 lakhs on its subsidiary Lyka BDR International Limited due to continuous operational losses and eroding net worth. This write-off covers the entire equity investment (Rs. 1,469.05 lakhs) and unsecured loans (Rs. 832.39 lakhs). Additionally, the NCLT has sanctioned the merger of Lyka Export Limited with the company (order dated March 16, 2026), with a record date of June 4, 2026 for share allotment. The auditors issued an unmodified (clean) opinion on the financial statements.
The significant impairment loss reflects weakness in the international subsidiary operations, which may weigh on investor sentiment. However, the merger with Lyka Export Limited could simplify the group structure. The company remains loss-making at the net level despite reasonable revenue scale.